Lupin and Natco Receive FDA Approval for Eribulin Mesylate Injection
Global pharmaceutical major Lupin Limited, in partnership with alliance partner Natco Pharma Limited, announced that they have received approval from the United States Food and Drug Administration (U.S. FDA). The approval pertains to Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.The approved product is the bioequivalent of Eisai, Inc.'s reference listed drug (RLD), Halaven® Injection. This medication is designed for treating specific conditions in advanced cancer patients.Eribulin Mesylate Injection has been indicated for the treatment of adults suffering from metastatic breast cancer. These...